Traders sold shares of Becton Dickinson and Co (NYSE:BDX) on strength during trading hours on Monday after an insider sold shares in the company. $105.46 million flowed into the stock on the tick-up and $190.09 million flowed out of the stock on the tick-down, for a money net flow of $84.63 million out of the stock. Of all equities tracked, Becton Dickinson and had the 0th highest net out-flow for the day. Becton Dickinson and traded up $1.75 for the day and closed at $218.89Specifically, Director Timothy M. Ring sold 269,661 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total value of $58,737,559.02. Following the sale, the director now directly owns 295,753 shares in the company, valued at approximately $64,420,918.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.00% of the company’s stock.

Several analysts have issued reports on the stock. Morgan Stanley increased their target price on shares of Becton Dickinson and from $245.00 to $250.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 7th. Piper Jaffray Companies restated an “overweight” rating and set a $260.00 price objective (up previously from $223.00) on shares of Becton Dickinson and in a research report on Tuesday, February 6th. Zacks Investment Research upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price objective on the stock in a research report on Wednesday, January 3rd. Evercore ISI started coverage on shares of Becton Dickinson and in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $245.00 price objective on the stock. Finally, Deutsche Bank set a $260.00 price objective on shares of Becton Dickinson and and gave the company a “buy” rating in a research report on Friday, December 29th. Four analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $237.27.

The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.93 and a current ratio of 1.54. The firm has a market cap of $50,220.00, a PE ratio of 167.09, a price-to-earnings-growth ratio of 1.49 and a beta of 1.12.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, topping analysts’ consensus estimates of $2.41 by $0.07. The company had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the company earned $2.33 EPS. analysts forecast that Becton Dickinson and Co will post 10.95 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be given a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.37%. The ex-dividend date of this dividend is Thursday, March 8th. Becton Dickinson and’s payout ratio is presently 229.01%.

A number of large investors have recently modified their holdings of BDX. Northern Trust Corp raised its position in Becton Dickinson and by 4.0% in the 2nd quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock worth $549,028,000 after purchasing an additional 106,966 shares during the period. Vanguard Group Inc. raised its position in Becton Dickinson and by 8.5% in the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after purchasing an additional 1,353,780 shares during the period. Quantum Capital Management raised its position in Becton Dickinson and by 7.3% in the 2nd quarter. Quantum Capital Management now owns 1,499 shares of the medical instruments supplier’s stock worth $292,000 after purchasing an additional 102 shares during the period. ETRADE Capital Management LLC raised its position in Becton Dickinson and by 19.6% in the 2nd quarter. ETRADE Capital Management LLC now owns 14,889 shares of the medical instruments supplier’s stock worth $2,905,000 after purchasing an additional 2,437 shares during the period. Finally, TIAA FSB purchased a new position in Becton Dickinson and in the 2nd quarter worth $7,373,000. Institutional investors own 75.56% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://theolympiareport.com/2018/02/13/investors-sell-becton-dickinson-and-bdx-on-strength-after-insider-selling.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.